Praluent (alirocumab), is a PCSK9 inhibitor used to treat high cholesterol in certain adults and children, including those with a genetic condition called familial hypercholesterolemia. The medication also helps lower the risk of heart attack, stroke, and hospitalization for chest pain in adults with heart disease. Praluent (alirocumab) is injected under the skin in the thigh, stomach, or upper arm every 2 weeks or 4 weeks, depending on your dose. Common side effects include injection-site reactions, flu or flu-like symptoms (e.g. sneezing, coughing, runny nose), and diarrhea.
Lower the risk of heart attack, stroke, and hospitalization for chest pain (angina) in adults with heart disease
High cholesterol (including heterozygous familial hypercholesterolemia (HeFH)) in adults, alone or with diet and other cholesterol-lowering medications
Homozygous familial hypercholesterolemia (HoFH) in adults, along with other cholesterol-lowering medications
Heterozygous familial hypercholesterolemia (HeFH) in children ages 8 and older, along with diet and other cholesterol-lowering medications
Praluent (alirocumab) is a PCSK9 inhibitor, which means it blocks a protein called PCSK9. Normally, PCSK9 prevents the liver from removing LDL cholesterol from the blood. By blocking PCSK9, Praluent (alirocumab) helps your body clear out more LDL cholesterol, leading to lower cholesterol levels.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Lowers LDL ("bad") cholesterol by about 50% to 60%
Reduces the risk of heart problems in adults with heart disease
Used alone or with other cholesterol-lowering medications
Given either every 2 or 4 weeks
Must be injected under the skin
Side effects include injection-site reactions, flu, and diarrhea
Potential for serious allergic reactions
Not known if safe during pregnancy or breastfeeding
Mark your calendar for prescriber visits and blood tests while taking Praluent (alirocumab). Your prescriber will check your cholesterol levels and might adjust your dose based on your lab results.
Follow a healthy and balanced diet low in fat and exercise regularly while taking Praluent (alirocumab). Doing so will help you get the most benefit out of the medication.
Praluent (alirocumab) can cause serious allergic reactions, like swelling of the face, lips, or throat. Stop using it and get medical help right away if you have trouble breathing or a severe rash.
It's not fully known if Praluent (alirocumab) is safe in pregnancy. Animal studies show no harm, but discuss to your prescriber about the risks and benefits.
Though likely safe, Praluent (alirocumab) while breastfeeding isn't well studied. Talk to your prescriber or OB-GYN provider, especially if you're nursing a newborn or premature baby.
Store Praluent (alirocumab) in the refrigerator and its original carton to protect it from light. It can also be kept at room temperature for up to 30 days.
Tips for what to do if you miss a dose:
If you miss a dose and it's been 7 days or less, take Praluent (alirocumab) as soon as possible and continue with your regular schedule.
If more than 7 days have passed and you inject Praluent (alirocumab) every 2 weeks, skip the missed dose and and take your next dose at the usual time.
If more than 7 days have passed and you inject Praluent (alirocumab) every 4 weeks, give yourself a dose and start a new schedule from this date.
How to use Praluent (alirocumab):
Make sure you know how to use Praluent (alirocumab). Watch this instructional video and read the instructions for use for the 75 mg pen or 150 mg pen and contact a member of your care team if you have any questions.
Check your medication strength: Praluent (alirocumab)] comes in 75 mg/mL and 150 mg/mL. If your dose is 300 mg, you’ll need two injections using different sites.
When it's time for a dose, take the pen out of the refrigerator and let it warm to room temperature for 30 to 40 minutes. Don't warm it up in the microwave, sun, or hot water since it can damage the medication.
Pick an injection site (thigh, stomach, or upper arm) and clean it with an alcohol wipe. Be sure to rotate injection sites with each dose to avoid irritation. Don't inject into tender, bruised, hard, or red skin, or areas with visible veins, scars, or stretch marks.
Inject at a 90° angle by pressing the yellow safety cover onto your skin until it's no longer visible. Once you hear a click, hold the pen in place until the dose window turns yellow, which can take about 20 seconds.
Throw away used needles pens in a sharps container or a sturdy plastic container, such as an empty milk carton or laundry detergent bottle. Don't throw them away in your trash can.
Praluent (alirocumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Praluent (alirocumab) can cause serious allergic reactions, including life-threatening ones like anaphylaxis. Symptoms include rash, itching, hives, facial swelling, and trouble breathing. If you experience any signs of a serious allergic reaction, stop using the medication immediately and get medical help right away.
Praluent (alirocumab) is given as an injection under the skin in the thigh, stomach, or upper arm.
Adults:
High cholesterol or HeFH: The typical starting dose is 75 mg every 2 weeks or 300 mg every 4 weeks. If your LDL is still high, your prescriber might raise your dose to 150 mg every 2 weeks
HeFH and undergoing LDL apheresis or HoFH: The typical dose is 150 mg every 2 weeks.
Children ages 8 and older with HeFH:
Weigh less than 110 lbs (50 kg): The typical dose is 150 mg every 4 weeks. If your child's LDL is still high, their prescriber might change the dose to 75 mg every 2 weeks.
Weigh 110 lbs (50 kg) or more: The typical dose is 300 mg every 4 weeks. If your child's LDL is still high, their prescriber might change the dose to 150 mg every 2 weeks.
Lower the risk of heart attack, stroke, and hospitalization for chest pain (angina) in adults with heart disease
High cholesterol (including heterozygous familial hypercholesterolemia (HeFH)) in adults, alone or with diet and other cholesterol-lowering medications
Homozygous familial hypercholesterolemia (HoFH) in adults, along with other cholesterol-lowering medications
Heterozygous familial hypercholesterolemia (HeFH) in children ages 8 and older, along with diet and other cholesterol-lowering medications
High cholesterol in adults
Inherited condition causing extremely high cholesterol (heterozygous and homozygous familial hypercholesterolemia) in people aged 10 years and older
Lower the risk of heart attack, stroke, and the need for heart procedures (like stent placement) in adults with known heart disease
High cholesterol, including heterozygous familial hypercholesterolemia (HeFH), in adults - as an add-on to a heart-healthy diet and statin therapy
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
American Heart Association. (2024). What is familial hypercholesterolemia?
Carugo, S., et al. (2022). PCSK9 inhibition and risk of diabetes: Should we worry? Current Atherosclerosis Reports.
Drugs and Lactation Database (LactMed®). (2023). Alirocumab.
Family Heart Foundation. (n.d.). Homozygous FH.
Family Heart Foundation. (n.d.). Lipoprotein apheresis.
Family Heart Foundation. (2014). What is heterozygous familial hypercholesterolemia?
Leiter, L. A., et al. (2017). Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes.
McDonagh, M., et al. (2016). A systematic review of PCSK9 inhibitors alirocumab and evolocumab. Journal of Managed Care & Specialty Pharmacy.
MotherToBaby. (2024). Alirocumab (Praluent®).
Pokhrel, B., et al. (2024). PCSK9 inhibitors.
Regeneron Pharmaceuticals, Inc. (2024). How to use Praluent.
Regeneron Pharmaceuticals, Inc. (2024). Instructions for use: Praluent® (PRAHL-u-ent) (alirocumab) injection for subcutaneous injection single-dose pre-filled pen (75 mg/mL).
Sanofi-Aventis U.S. LLC. (2024). Praluent- alirocumab injection, solution [package insert]. DailyMed.
Schwartz, G. G., et al. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine.
Snyder, C., et al. (2025). Inherited high cholesterol in children: What families need to know. Healthychildren.org.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.